Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials

Section of Preventive Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.

OBJECTIVES. This work was done to determine the role of hypertension treatment in the prevention of disease progression, left ventricular hypertrophy and congestive heart failure. BACKGROUND. Lowering of blood pressure in hypertensive patients has been reported to reduce morbidity and mortality from strokes and myocardial infarction. Data on primary prevention of disease progression, left ventricular hypertrophy and congestive heart failure have not previously been carefully quantified. METHODS. All the major long-term hypertension treatment trials over the past 20 years were reviewed. RESULTS. One thousand four hundred ninety-three of 13,342 subjects in the control groups compared with only 95 of 13,389 in the treated groups progressed from less severe to severe hypertension. The incidence of left ventricular hypertrophy in treated compared with control or placebo subjects was 140 of 6,150 and 216 of 6,098 subjects, respectively; congestive heart failure occurred in 240 of 6,923 subjects in the control group compared with only 112 of 6,914 treated subjects. CONCLUSIONS. The lowering of blood pressure over a 3- to 5-year period of time is effective in preventing severe disease, left ventricular hypertrophy and congestive heart failure in addition to strokes and myocardial infarction. In an era when expensive and often complicated methods are being used to prevent recurrence of congestive heart failure or myocardial infarction, it is important to highlight the role of antihypertensive therapy in primary prevention.

This article has been cited by other articles:

				P. Verdecchia, F. Angeli, C. Cavallini, R. Gattobigio, G. Gentile, J. A. Staessen, and G. Reboldi Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis Eur. Heart J., March 2, 2009; 30(6): 679 - 688. [Abstract] [Full Text] [PDF]

				D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]

				A. Phrommintikul, L. Tran, A. Kompa, B. Wang, A. Adrahtas, D. Cantwell, D. J. Kelly, and H. Krum Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1804 - H1814. [Abstract] [Full Text] [PDF]

				C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]

				C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]

				A. P. Pilbrow, B. R. Palmer, C. M. Frampton, T. G. Yandle, R. W. Troughton, E. Campbell, L. Skelton, J. G. Lainchbury, A. M. Richards, and V. A. Cameron Angiotensinogen M235T and T174M Gene Polymorphisms in Combination Doubles the Risk of Mortality in Heart Failure Hypertension, February 1, 2007; 49(2): 322 - 327. [Abstract] [Full Text] [PDF]

				N M Hawkins, D Wang, J J V McMurray, M A Pfeffer, K Swedberg, C B Granger, S Yusuf, S J Pocock, J Ostergren, E L Michelson, et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme Heart, January 1, 2007; 93(1): 59 - 64. [Abstract] [Full Text] [PDF]

				U. Dahlstrom Frequent non-cardiac comorbidities in patients with chronic heart failure Eur J Heart Fail, March 16, 2005; 7(3): 309 - 316. [Abstract] [Full Text] [PDF]

				P. Verdecchia, F. Angeli, R. Gattobigio, M. Sardone, and C. Porcellati Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension: Prevalence, Determinants, and Prognostic Value Hypertension, March 1, 2005; 45(3): 412 - 418. [Abstract] [Full Text] [PDF]

				M. Moser Results of ALLHAT: Is This the Final Answer Regarding Initial Antihypertensive Drug Therapy? Arch Intern Med, June 9, 2003; 163(11): 1269 - 1273. [Full Text] [PDF]

				PROGRESS Collaborative Group Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease Eur. Heart J., March 1, 2003; 24(5): 475 - 484. [Abstract] [Full Text] [PDF]

				T. Nishikimi, K. Tadokoro, Y. Mori, X. Wang, K. Akimoto, F. Yoshihara, N. Minamino, K. Kangawa, and H. Matsuoka Ventricular Adrenomedullin System in the Transition From LVH to Heart Failure in Rats Hypertension, March 1, 2003; 41(3): 512 - 518. [Abstract] [Full Text] [PDF]

				A. W. Haider, M. G. Larson, S. S. Franklin, and D. Levy Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study Ann Intern Med, January 7, 2003; 138(1): 10 - 16. [Abstract] [Full Text] [PDF]

				D. M. Lloyd-Jones, M. G. Larson, E. P. Leip, A. Beiser, R. B. D'Agostino, W. B. Kannel, J. M. Murabito, R. S. Vasan, E. J. Benjamin, and D. Levy Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study Circulation, December 10, 2002; 106(24): 3068 - 3072. [Abstract] [Full Text] [PDF]

				D A Wood Preventing clinical heart failure: the rationale and scientific evidence Heart, October 1, 2002; 88(90002): ii15 - 22. [Full Text] [PDF]

				H. Krum, H. Nolly, D. Workman, W. He, B. Roniker, S. Krause, and K. Fakouhi Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients Hypertension, August 1, 2002; 40(2): 117 - 123. [Abstract] [Full Text] [PDF]

				S. D. Fihn, S. V. Williams, J. Daley, and R. J. Gibbons Guidelines for the Management of Patients with Chronic Stable Angina: Treatment Ann Intern Med, October 16, 2001; 135(8_Part_1): 616 - 632. [Abstract] [Full Text] [PDF]

				C Hengstenberg, S.R Holmer, B Mayer, S Engel, A Schneider, H Lowel, G.A.J Riegger, and H Schunkert Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease Eur. Heart J., June 1, 2001; 22(11): 926 - 933. [Abstract] [PDF]

				W. J. Elliott, D. R. Weir, and H. R. Black Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients Arch Intern Med, May 8, 2000; 160(9): 1277 - 1283. [Abstract] [Full Text] [PDF]

				H. M. Krumholz, D. W. Baker, C. M. Ashton, S. B. Dunbar, G. C. Friesinger, E. P. Havranek, M. A. Hlatky, M. Konstam, D. L. Ordin, I. L. Pina, et al. Evaluating Quality of Care for Patients With Heart Failure Circulation, March 28, 2000; 101 (12): e122 - e140. [Full Text] [PDF]

				D. Levy, C. N. Bairey Merz, R. J. Cody, F. M. Fouad-Tarazi, C. K. Francis, M. A. Pfeffer, N. A. Scott, H. J. C. Swan, M. P. Taylor, and M. H. Weinberger Hypertension detection, treatment and control: A call to action for cardiovascular specialists J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1360 - 1362. [Full Text] [PDF]

				M. Moser National Recommendations for the Pharmacological Treatment of Hypertension: Should They Be Revised? Arch Intern Med, July 12, 1999; 159(13): 1403 - 1406. [Full Text] [PDF]

				R. J. Gibbons, K. Chatterjee, J. Daley, J. S. Douglas, S. D. Fihn, J. M. Gardin, M. A. Grunwald, D. Levy, B. W. Lytle, R. A. O'Rourke, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina) J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2092 - 2197. [Full Text] [PDF]

				M. Moser Why Are Physicians Not Prescribing Diuretics More Frequently in the Management of Hypertension? JAMA, June 10, 1998; 279(22): 1813 - 1816. [Abstract] [Full Text] [PDF]

				The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med, November 24, 1997; 157(21): 2413 - 2446. [Abstract] [PDF]

				L. E. Ramsay The Hypertension Detection and Follow-up Program: 17 Years On JAMA, January 8, 1997; 277(2): 167 - 170. [Abstract] [PDF]

				R. S. Vasan and D. Levy The Role of Hypertension in the Pathogenesis of Heart Failure: A Clinical Mechanistic Overview Arch Intern Med, September 9, 1996; 156(16): 1789 - 1796. [Abstract] [PDF]

				K. Wachtell, J. N. Bella, J. Rokkedal, V. Palmieri, V. Papademetriou, B. Dahlof, T. Aalto, E. Gerdts, and R. B. Devereux Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Circulation, March 5, 2002; 105(9): 1071 - 1076. [Abstract] [Full Text] [PDF]